|Bid||0.00 x 4000|
|Ask||0.00 x 1300|
|Day's Range||5.76 - 6.01|
|52 Week Range||3.92 - 21.71|
|Beta (3Y Monthly)||0.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.44|
− Once Weekly Oral Selinexor in Combination with Kyprolis® and Low Dose Dexamethasone Demonstrates 78% ORR in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma –.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 95,500 shares of Karyopharm’s common stock to seventeen newly-hired employees, with a grant date of May 31, 2019. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $5.64 per share, the closing price of Karyopharm’s common stock on May 31, 2019. Each stock option vests over four years, with 25% of the original number of shares underlying the stock option vesting on the one-year anniversary of the applicable employee’s employment commencement date and an additional 1/48th of the shares vesting monthly thereafter, subject to the employee’s continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.
NEWTON, Mass., May 28, 2019 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will.
-- Oral Presentation Highlighting Updated Data from the Phase 1b/2 STOMP Study Arm Evaluating Selinexor and Dexamethasone in Combination with Darzalex® in Patients with Relapsed.
NEWTON, Mass., May 15, 2019 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, congratulates its founder, President and Chief Scientific.
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost more than 25%. Facebook, which was the second most popular stock, lost 20% amid uncertainty regarding the interest rates and tech […]
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -29.76% and -79.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Newton, Massachusetts-based company said it had a loss of $1.09. The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment ...
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-- Conference Call Scheduled for Thursday, May 9, 2019 at 8:30 a.m. ET -- NEWTON, Mass., May 02, 2019 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) latest earnings update in December 2018 indicated co...
Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 14) Novartis AG (NYSE: NVS ) (announced resignation of ...
NEWTON, Mass., March 14, 2019 /PRNewswire/ -- Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for selinexor. The NDA, which is currently under Priority Review by the FDA, is seeking accelerated approval for selinexor in combination with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor (PI), one immunomodulatory agent (IMiD), and one anti-CD38 monoclonal antibody.
As Kenny Rogers sang, you've got to know when to hold 'em and know when to fold 'em… and sometimes when not to play a hand at all.
Billionaire investor Steven Cohen (Trades, Portfolio), who heads up hedge fund Point72 Asset Management, disclosed he upped his stake in Karyopharm Therapeutics Inc. (KPTI) on Feb. 22. Warning! GuruFocus has detected 5 Warning Signs with KPTI.